On The Pen: The Weekly Dose 5.28.24

On The Pen News: https://www.onthepen.com/blog

SHOW NOTES:
Ozempic study in New England Journal of Medicine:
Link: https://www.bloomberg.com/news/articles/2024-05-24/novo-s-ozempic-slashes-risk-of-death-in-kidney-disease-study

Compounding (tiktok video)
Link: https://www.abc.net.au/news/2024-05-22/compound-pharmacies-banned-weight-loss-drugs-replica-ozempic/103861108

Zealand Pharma:
Link: https://www.biospace.com/article/zealand-touts-phase-i-results-for-glp-1-glp-2-candidate-despite-modest-weight-loss-/

Inhaled GLP-1 medications
Link: https://www.biostock.se/en/2024/05/iconovo-initiates-development-of-inhaled-obesity-treatment/

Oral version of tirzepatide (tiktok video):
Link: https://ca.finance.yahoo.com/news/lexaria-awards-contract-third-glp-130500555.html

Mounjaro approved for China (tiktok video):
Link: https://www.bloomberg.com/news/articles/2024-05-21/china-clears-eli-lilly-s-weight-loss-drug-tirzepatide-only-for-diabetes

Eli Lilly announces capacity increase (tiktok video)
Link: https://investor.lilly.com/news-releases/news-release-details/lilly-increases-manufacturing-investment-9-billion-newest

GLP-1 usage by young people:
From 2020 to 2023, the number of U.S. adolescents and young adults using GLP-1 increased 600 percent — from roughly 8,700 peo